IGF2BP2 promotes lncRNA DANCR stability mediated glycolysis and affects the progression of FLT3-ITD + acute myeloid leukemia.


Journal

Apoptosis : an international journal on programmed cell death
ISSN: 1573-675X
Titre abrégé: Apoptosis
Pays: Netherlands
ID NLM: 9712129

Informations de publication

Date de publication:
08 2023
Historique:
accepted: 01 04 2023
medline: 12 7 2023
pubmed: 16 4 2023
entrez: 15 4 2023
Statut: ppublish

Résumé

Internal tandem duplication (ITD) is the most common type of FLT3 mutation (FLT3-ITD), accounting for about 25% of AML patients. The expression of DANCR in FLT3-ITD AML had not been paid attention to, and whether its regulatory relationship with IGF2BP2 can affect the progression of FLT3-ITD AML was unclear. Our study sought to verify the biological role of IGF2BP2 as an m6A reading protein in FLT3-ITD AML. To further explore the role and mechanism of DANCR in AML, and provide a basis for the screening of biomarkers and the development of targeted drugs. The results show that IGF2BP2 was upregulated in FLT3-ITD+ AML patients and cells. Si-IGF2BP2 could inhibit the proliferation, glycolytic and promote the apoptosis in MV4-11 cells. IGF2BP2 could promote the DANCR RNA stability. This discovery will provide new horizons for early screening and targeted therapy of FLT3-ITD+ AML.

Identifiants

pubmed: 37060505
doi: 10.1007/s10495-023-01846-0
pii: 10.1007/s10495-023-01846-0
pmc: PMC10333402
doi:

Substances chimiques

RNA, Long Noncoding 0
Biomarkers 0
fms-Like Tyrosine Kinase 3 EC 2.7.10.1
FLT3 protein, human EC 2.7.10.1
IGF2BP2 protein, human 0
RNA-Binding Proteins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1035-1047

Informations de copyright

© 2023. The Author(s).

Références

Trends Biochem Sci. 2014 Aug;39(8):347-54
pubmed: 25037503
Hematology. 2021 Dec;26(1):840-847
pubmed: 34674612
J Hematol Oncol. 2021 Apr 26;14(1):70
pubmed: 33902674
Nature. 2021 May;593(7860):597-601
pubmed: 33902106
Blood. 2021 Dec 30;138(26):2838-2852
pubmed: 34255814
Clin Chim Acta. 2018 Oct;485:229-233
pubmed: 29981289
J Cell Physiol. 2019 Jun;234(6):9105-9117
pubmed: 30362551
J Clin Oncol. 2011 Feb 10;29(5):475-86
pubmed: 21220609
Cell Stem Cell. 2018 Feb 1;22(2):191-205.e9
pubmed: 29290617
Front Cell Dev Biol. 2022 Jan 24;9:659228
pubmed: 35141227
Int J Radiat Biol. 2019 Jul;95(7):912-919
pubmed: 30822194
Sci Rep. 2021 Dec 7;11(1):23565
pubmed: 34876631
Blood Cancer J. 2021 May 27;11(5):104
pubmed: 34045454
Haematologica. 2021 Mar 01;106(3):664-670
pubmed: 33472354
Eur Rev Med Pharmacol Sci. 2020 Nov;24(22):11594-11601
pubmed: 33275226
iScience. 2021 Dec 25;25(1):103680
pubmed: 35036870
Front Oncol. 2019 Oct 18;9:1048
pubmed: 31681586
Cancer Cell. 2016 Jul 11;30(1):43-58
pubmed: 27344946
Cancer Cell Int. 2021 Feb 10;21(1):99
pubmed: 33568150
Anticancer Drugs. 2022 Jan 1;33(1):e207-e217
pubmed: 34407052
Oncogene. 2021 Feb;40(8):1531-1541
pubmed: 33452460
Int J Mol Sci. 2019 Nov 16;20(22):
pubmed: 31744051
Mol Cancer. 2013 Dec 03;12:152
pubmed: 24298908
Mol Cancer. 2019 Dec 2;18(1):174
pubmed: 31791342
Cancer Cell. 2019 Apr 15;35(4):677-691.e10
pubmed: 30991027
Sci Rep. 2021 Oct 20;11(1):20745
pubmed: 34671057
Mol Oncol. 2021 Apr;15(4):1203-1216
pubmed: 33638615
Cell Death Differ. 2022 Jun;29(6):1137-1151
pubmed: 34999731
Cancer Discov. 2021 Jun;11(6):1582-1599
pubmed: 33436370
Blood. 2021 Jun 24;137(25):3518-3532
pubmed: 33720355
Cancer Control. 2018 Jan-Mar;25(1):1073274818769849
pubmed: 29651883
Front Cell Dev Biol. 2021 Oct 15;9:753706
pubmed: 34722539
Front Oncol. 2014 Mar 18;4:55
pubmed: 24672775
J Clin Invest. 2021 Jan 4;131(1):
pubmed: 33108352
Cell Death Differ. 2020 Jun;27(6):1782-1794
pubmed: 31804607
Clin Transl Med. 2021 Jun;11(6):e426
pubmed: 34185427
Cancer Med. 2018 Dec;7(12):6124-6136
pubmed: 30403008
Cancer Commun (Lond). 2021 Feb;41(2):109-120
pubmed: 33119215
Cancer Cell. 2021 Jul 12;39(7):958-972.e8
pubmed: 34048709
Signal Transduct Target Ther. 2021 May 24;6(1):186
pubmed: 34024909
Mol Cell. 2021 Mar 4;81(5):922-939.e9
pubmed: 33434505
J Cancer Educ. 2013 Sep;28(3):454-7
pubmed: 23728993

Auteurs

Shenghao Wu (S)

Department of Hematology, The Dingli Clinical College of Wenzhou Medical University (The Second Affiliated Hospital of Shanghai University, Wenzhou Central Hospital), Wenzhou city, Zhejiang Province, China. wushenghao30@gmail.com.

Changwei Chi (C)

Department of Hematology, The Dingli Clinical College of Wenzhou Medical University (The Second Affiliated Hospital of Shanghai University, Wenzhou Central Hospital), Wenzhou city, Zhejiang Province, China.

Shanshan Weng (S)

Department of Hematology, The Dingli Clinical College of Wenzhou Medical University (The Second Affiliated Hospital of Shanghai University, Wenzhou Central Hospital), Wenzhou city, Zhejiang Province, China.

Wenjin Zhou (W)

Department of Hematology, The Dingli Clinical College of Wenzhou Medical University (The Second Affiliated Hospital of Shanghai University, Wenzhou Central Hospital), Wenzhou city, Zhejiang Province, China.

Zhen Liu (Z)

Department of Hematology, The Dingli Clinical College of Wenzhou Medical University (The Second Affiliated Hospital of Shanghai University, Wenzhou Central Hospital), Wenzhou city, Zhejiang Province, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH